We enrolled 46 tumors from surgically resected patients with NSCLC who had received TKI therapy to examine the possibility of an association between the expression of PD-L1 and YAP1 and with tumor response to TKI therapy in these patients. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.